U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H17NO2
Molecular Weight 159.2261
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PREGABALIN

SMILES

CC(C)C[C@H](CN)CC(O)=O

InChI

InChIKey=AYXYPKUFHZROOJ-ZETCQYMHSA-N
InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H17NO2
Molecular Weight 159.2261
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17126531

Pregabalin, marketed under the brand name Lyrica among others. LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) Postherpetic neuralgia (PHN); Adjunctive therapy for adult patients with partial onset seizures; Fibromyalgia; Neuropathic pain associated with spinal cord injury. It has been shown the clinical effects of pregabalin are likely due to direct and selective interactions with α(2)δ-1 and α(2)δ-2 subunits of voltage-gated calcium channels. While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid (GABA), it does not bind directly to GABAA, GABAB, or benzodiazepine receptors, does not augment GABAA responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport. Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.

CNS Activity

Curator's Comment: Known to be CNS penetrant in mouse, rat, monkey. Human data not available

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

2004
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

2004
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

2004
Palliative
LYRICA

Approved Use

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1) Postherpetic neuralgia (PHN) (1) Adjunctive therapy for adult patients with partial onset seizures (1) Fibromyalgia (1) Neuropathic pain associated with spinal cord injury (1)

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4568.68 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREGABALIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29831.454 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREGABALIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
unknown, oral
PREGABALIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Other AEs: Vision blurred, Nausea...
Other AEs:
Vision blurred (moderate, 1 patient)
Nausea (moderate, 1 patient)
Dizziness (mild, 4 patients)
Dysarthria (moderate, 1 patient)
Headache (mild, 2 patients)
Sources:
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 53.91 years
n = 22
Health Status: unhealthy
Condition: Essential Tremor
Age Group: 53.91 years
Sex: M+F
Population Size: 22
Sources:
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Disc. AE: Dizziness, Somnolence...
AEs leading to
discontinuation/dose reduction:
Dizziness (3.47%)
Somnolence (2.76%)
Asthenia (0.82%)
Confusion (0.72%)
Peripheral edema (0.61%)
Headache (1.12%)
Amblyopia (0.82%)
Dry mouth (0.72%)
Nausea (0.72%)
Infection (0.41%)
Ataxia (0.41%)
Neuropathy (0.41%)
Tremor (0.41%)
Constipation (0.31%)
Diarrhea (0.31%)
Incoordination (0.31%)
Abnormal thinking (0.31%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache mild, 2 patients
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Dizziness mild, 4 patients
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Dysarthria moderate, 1 patient
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Nausea moderate, 1 patient
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Vision blurred moderate, 1 patient
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 24.8 years
n = 10
Health Status: healthy
Age Group: 24.8 years
Sex: M
Population Size: 10
Sources:
Abnormal thinking 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Constipation 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Diarrhea 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Incoordination 0.31%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Ataxia 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Infection 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Neuropathy 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Tremor 0.41%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Peripheral edema 0.61%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Confusion 0.72%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Dry mouth 0.72%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Nausea 0.72%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Amblyopia 0.82%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Asthenia 0.82%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Headache 1.12%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Somnolence 2.76%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Dizziness 3.47%
Disc. AE
150 mg 1 times / day steady, oral
unhealthy, adult
n = 979
Overview

OverviewOther

Drug as perpetrator​Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
New single-isomer compounds on the horizon.
2002 Apr
Gateways to clinical trials.
2002 Dec
Pharmacotherapy of social phobia.
2003
Pregabalin: a new anxiolytic.
2003 Apr
Highly enantioselective, catalytic conjugate addition of cyanide to alpha,beta-unsaturated imides.
2003 Apr 16
Patient pages. Treatment of postherpetic neuralgia.
2003 Apr 22
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
2003 Apr 22
Synthesis of both enantiomers of a P-chirogenic 1,2-bisphospholanoethane ligand via convergent routes and application to rhodium-catalyzed asymmetric hydrogenation of CI-1008 (pregabalin).
2003 Aug 27
Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited.
2003 Dec
Gateways to clinical trials.
2003 Jan-Feb
Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat.
2003 Jul
Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations.
2003 Jul
An enantioselective synthesis of (S)-(+)-3-aminomethyl-5-methylhexanoic acid via asymmetric hydrogenation.
2003 Jul 11
Gateways to clinical trials.
2003 Jul-Aug
GABA-ergic drugs: exit stage left, enter stage right.
2003 Jun
Gateways to clinical trials.
2003 Jun
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
2003 Jun
Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures.
2003 Jun
Gateways to clinical trials. March 2003.
2003 Mar
Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
2003 Mar
Gateways to clinical trials.
2003 May
Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures.
2003 May 27
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
2003 Nov
Gateways to clinical trials.
2003 Oct
Gateways to clinical trials.
2003 Sep
Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.
2003 Sep
Pregabalin: in the treatment of painful diabetic peripheral neuropathy.
2004
[New molecular targets in pharmacological treatment of anxiety disorders].
2004
Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators.
2004 Aug
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.
2004 Aug
Pharmaceutical treatment options for fibromyalgia.
2004 Aug
A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats.
2004 Aug 4
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
2004 Dec 14
Pregabalin (Pfizer).
2004 Jan
Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.
2004 Jan
Gateways to clinical trials.
2004 Jul-Aug
Neuromodulating drugs for the symptomatic treatment of neuropathic pain.
2004 Jun
Gateways to clinical trials.
2004 Mar
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
2004 May
American Chemical Society--227th annual meeting. Neuroprotection. 28 March - 1 April 2004, Anaheim, CA, USA.
2004 May
[How neuropathic is sciatica? The mixed pain concept].
2004 May
Highly selective asymmetric hydrogenation using a three hindered quadrant bisphosphine rhodium catalyst.
2004 May 19
[New options in the treatment of various forms of diabetic neuropathy].
2004 May 20
Gateways to clinical trials.
2004 Nov
Gateways to clinical trials.
2004 Oct
'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in in the treatment of post-operative pain.
2004 Oct
Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection.
2004 Oct 25
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
2004 Sep 28
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
2004 Sep-Oct
Pregabalin: in the treatment of postherpetic neuralgia.
2005
Patents

Sample Use Guides

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy: The maximum recommended dose is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Postherpetic Neuralgia: The recommended dose is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 75 mg two times a day, or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Adjunctive Therapy for Adult Patients with Partial Onset Seizures: LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Management of Fibromyalgia: The recommended dose is 300 to 450 mg/day. Begin dosing at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Neuropathic Pain Associated with Spinal Cord Injury: The recommended dose range is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Pregabalin antagonizes the neurotoxic effects of copper
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:45:33 GMT 2023
Edited
by admin
on Fri Dec 15 15:45:33 GMT 2023
Record UNII
55JG375S6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PREGABALIN
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NSC-759256
Code English
PREGABALIN [ORANGE BOOK]
Common Name English
(S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID
Systematic Name English
PREGABALIN [USAN]
Common Name English
PREGABALIN [VANDF]
Common Name English
PREGABALIN [JAN]
Common Name English
PREGABALIN SANDOZ
Brand Name English
LYRICA CR
Brand Name English
PREGABALIN [MART.]
Common Name English
VRONOGABIC
Common Name English
PREGABALIN MYLAN
Brand Name English
pregabalin [INN]
Common Name English
CI-1008
Code English
Pregabalin [WHO-DD]
Common Name English
PREGABALIN [HSDB]
Common Name English
PREGABALIN ZENTIVA
Brand Name English
LYRICA
Brand Name English
PREGABALIN [MI]
Common Name English
PREGABALIN MYLAN PHARMA
Brand Name English
PD-144723
Code English
PREGABALIN [USP-RS]
Common Name English
PREGABALIN SANDOZ GMBH
Brand Name English
PREGABALIN [USP MONOGRAPH]
Common Name English
YNP-1807
Code English
PREGABALIN [EP MONOGRAPH]
Common Name English
PREGABALIN [EMA EPAR]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS PREGABALIN PFIZER (AUTHORIZED: NEURALGIA)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS PREGABALIN ZENTIVA (AUTHORIZED: EPILEPSY)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
WHO-ATC N03AX16
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
WHO-VATC QN03AX16
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS PREGABALIN SANDOZ GMBH (AUTHORIZED: EPILEPSY)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
NCI_THESAURUS C264
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
LIVERTOX NBK548053
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS PREGABALIN MYLAN PHARMA (AUTHORIZED: EPILEPSY)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS LYRICA (AUTHORIZED: ANXIETY DISORDERS)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS LYRICA (AUTHORIZED: NEURALGIA)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS PREGABALIN MYLAN (AUTHORIZED: EPILEPSY)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
NCI_THESAURUS C2198
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
DEA NO. 2782
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS PREGABALIN SANDOZ (AUTHORIZED: EPILEPSY)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
EMA ASSESSMENT REPORTS LYRICA (AUTHORIZED: EPILEPSY)
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
Code System Code Type Description
DRUG CENTRAL
2255
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
FDA UNII
55JG375S6M
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
NCI_THESAURUS
C64625
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
LACTMED
Pregabalin
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
EVMPD
SUB10023MIG
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
IUPHAR
5484
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
CAS
148553-50-8
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
NSC
759256
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
MESH
C080245
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
HSDB
7530
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
RS_ITEM_NUM
1559618
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
DRUG BANK
DB00230
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
ChEMBL
CHEMBL1059
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045950
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
DAILYMED
55JG375S6M
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
RXCUI
187832
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY RxNorm
PUBCHEM
5486971
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
USAN
HH-23
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
MERCK INDEX
m9113
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY Merck Index
SMS_ID
100000091845
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
INN
7643
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
CHEBI
64356
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
WIKIPEDIA
PREGABALIN
Created by admin on Fri Dec 15 15:45:33 GMT 2023 , Edited by admin on Fri Dec 15 15:45:33 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
EXCRETED UNCHANGED
URINE
TARGET -> INHIBITOR
ReduceS depolarization-induced calcium influx at nerve terminals, with a consequential reduction in the release of several excitatory neurotransmitters, including glutamate, noradrenaline, substance P, and CGRP.
IC50
INNOVATOR->PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
TARGET->LIGAND
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
ENANTIOMERIC PURITY/HPLC
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC